KMB Dividend Calculator

About KMB

Kimberly-Clark Corporation — ticker KMB — is a US consumer staples manufacturer best known for a portfolio of personal-care and tissue brands that have been part of American households for generations. The company was founded in 1872 in Neenah, Wisconsin, and now trades on the NYSE with a market capitalization in the $40-45 billion range. KMB is a Dividend Aristocrat with a streak of more than fifty consecutive years of annual dividend increases, placing it in the same long-streak bracket as Procter & Gamble (PG), Coca-Cola (KO), Colgate-Palmolive (CL), and Johnson & Johnson (JNJ). The streak began in the early 1970s and has continued through every recession, market crash, and global disruption since then. That continuity is the central reason KMB occupies a position in many income-focused portfolios despite recent stock-price weakness.

KMB operates in the Consumer Defensive sector, with revenue split across three operating segments. Personal Care accounts for roughly half of total revenue and includes the Huggies diaper franchise, Kotex feminine-care products, and Pull-Ups training pants — categories where KMB holds significant global market share. Consumer Tissue contributes about thirty percent of revenue through the Kleenex facial-tissue brand, Cottonelle bath tissue, Viva paper towels, and the Scott brand of value-tier paper products. K-C Professional, the third segment, accounts for the remaining twenty percent and sells Scott and Kleenex commercial tissue along with workplace-hygiene products to facilities, offices, and institutions rather than to retail consumers. Geographically, revenue is split roughly evenly between the United States and international markets, which introduces meaningful currency translation effects in any given quarter.

The margin profile sits in the middle of the consumer-staples cohort. Gross margins typically run in the thirty to thirty-two percent range — lower than CL's roughly sixty percent because tissue and diaper categories carry less pricing power than premium oral care, and consumer-tissue customers can substitute between private-label and branded options more readily than in toothpaste. Operating margins typically sit around seventeen percent. The payout ratio runs between fifty-five and seventy percent of earnings in a typical year, which is a sustainable range for a mature consumer staple but leaves less headroom for a downturn than a lower-payout name would carry. Credit-rating agencies have maintained KMB at investment-grade ratings throughout the streak. Expense ratio is not applicable to individual stocks — the figure you'll see in the calculator above is zero, since there is no fund wrapper between you and the underlying shares.

One structural development worth flagging directly. In 2024 KMB announced a major restructuring intended to separate the consumer-products business from the global supplier business — a multi-year process that may eventually affect the corporate structure under which dividends are paid. As of the most recent reporting period both pieces continue to operate under the KMB ticker and the dividend continues at the consolidated-company rate. How the eventual separation is structured — clean spinoff, partial divestiture, or alternative arrangement — and how dividend allocation is handled between the resulting entities are open questions that long-term holders should track. The historical streak applies to the consolidated KMB as it has existed since 1872; post-separation dividend continuity for either resulting business is a matter for future disclosure.

How KMB pays dividends

KMB pays cash dividends quarterly, on a March–June–September–December ex-date cadence with pay dates that fall on the first business day of the following month — typically April 1, July 1, October 1, and January 2. The board declares the per-share amount each quarter; the ex-dividend date typically falls in the first half of the third month of the quarter, and the pay date follows roughly two to three weeks later. Holders who own shares as of the close on the day before the ex-date receive the dividend; holders who buy on or after the ex-date wait for the next quarterly payment. On the ex-date the share price drops by approximately the distribution amount on the open, reflecting the fact that the company has paid the cash out of its balance sheet.

Holders who DRIP through their broker receive additional shares purchased at the prevailing market price around the pay date. Most major brokers offer fractional-share DRIP for KMB, so the full cash distribution is reinvested even when the per-share amount divided by the share price doesn't produce a whole number. The mechanics are identical to any other quarterly US dividend stock — there is no managed-distribution policy, no covered-call overlay, and no return of capital. The cash that funds the dividend comes from operating earnings: KMB collects revenue from personal-care, consumer-tissue, and K-C Professional sales, pays raw-material costs (pulp, packaging, freight), operating expenses, and taxes, services its debt, and the residual is available for capital return through the dividend and share repurchases.

Recent growth pattern: KMB has typically raised the quarterly per-share amount once per year, with the new rate taking effect on the first dividend payment following the announcement. The size of the annual hike has run in the low-single-digit range over the most recent five-year window — slower than the mid-single-digit pace some Aristocrats maintain, reflecting the input-cost pressure (pulp prices, packaging, freight) that has compressed margins through 2022-2024. Management has prioritized continuing the streak over accelerating the hike size, which is the structurally honest trade-off for a Dividend Aristocrat in a margin-pressured period. The calculator on this page uses the trailing five-year dividend growth rate to project the income line forward; you can override this with a custom growth rate if you want to model a more conservative or more optimistic path.

The current forward yield on KMB sits at the high end of the Dividend Aristocrat cohort. The structural source of that elevated yield is important to understand: it is not the product of accelerating dividend growth. The annual dividend hike has been modest, in line with the slow recent cadence. The elevated yield is the arithmetic result of share-price weakness — when the price denominator declines while the dividend numerator continues to grow, the yield ratio rises. The scenarios page covers this dynamic in detail. For purposes of the income projection on this page, the current yield is the relevant input for the year-one calculation; the long-term shape of the projection depends on whether the recent slow dividend-growth cadence continues or accelerates as input-cost pressure eventually normalizes.

Who KMB suits

KMB suits income-focused investors who want exposure to a long-streak Dividend Aristocrat at a point in the cycle when the price compression has produced an elevated entry yield. The current yield is meaningfully higher than KMB's own five-year average yield, and meaningfully higher than the yield typically available on broader-portfolio peers like PG. For a Path A dividend investor — a long-horizon holder who cares more about the income stream than about quarterly mark-to-market — the structural appeal is a fifty-plus-year hiker available at a yield that historically sat ten to one hundred fifty basis points lower.

The trade-off is the path of the share price itself. KMB stock has underperformed the broad market and the consumer-staples sector over recent five-year windows. The reasons are structural and worth naming: pulp and freight input costs have run elevated, private-label tissue competition has limited pricing power on the value end of the portfolio, the diaper category has faced declining US birth rate pressure on absolute volume, and the announced 2024 restructuring has introduced uncertainty about the eventual corporate structure. The dividend has continued growing through all of this, but the market has repriced the multiple downward — which is what shows up in the calculator's measured five-year share-price growth figure. Holders should understand that "current yield is elevated for the category" and "share price has been weak" are two sides of the same arithmetic, not independent facts.

In taxable accounts, KMB's dividends are qualified for the long-term capital-gains rate, given the standard sixty-day holding-period rule (the share must be held for more than sixty days during the 121-day window centered on the ex-date). Most buy-and-hold investors clear this threshold easily. In tax-advantaged accounts — IRAs, Roth IRAs, 401(k)s — the qualified-dividend treatment is moot because no current-year tax applies; the structural advantage of a long-running dividend grower is the compounding of share count via DRIP without tax friction.

Compared to dividend-focused ETFs like SCHD, KMB offers concentrated exposure to a single mature consumer-staples business rather than a diversified basket. A KMB investor accepts company-specific risk — including input-cost exposure to pulp markets, US private-label tissue competition, demographic pressure on the diaper category, currency translation effects on the roughly fifty percent of revenue generated outside the US dollar zone, and execution risk around the announced restructuring. SCHD, by contrast, holds roughly one hundred names with a single-stock cap; it sacrifices some yield to eliminate the concentration risk. Many income-focused investors hold both: KMB for the long-streak Aristocrat signal and the elevated entry yield, SCHD for the diversification.

KMB is generally considered a defensive holding because demand for diapers, tissue, and feminine-care products tends to be relatively insensitive to the economic cycle — these are recurring household purchases rather than discretionary spending. The defensive character is real, but the price action over the recent five-year window is a reminder that defensive demand does not guarantee defensive share-price behavior when the input-cost and competitive structure of the underlying business is under pressure. As with any single-stock position, this content is educational only; it is not a recommendation to buy, sell, or hold KMB, and individual circumstances vary.